Aqueous injectable solutions containing suramin sodium are manufactured for slow intravenous administration in equine and camelid trypanosomiasis protocols where such use is authorized or compounded under veterinary supervision. The bulk solution is typically compounded as a 10% w/v solution in Water for Injection, adjusted to pH 6.0–6.5 with 0.1 M sodium hydroxide or hydrochloric acid, and made isotonic to 280–320 mOsm/kg with sodium chloride. Solution preparation is carried out in a 316L stainless steel jacketed vessel at 15–25°C under nitrogen overlay to limit oxidative discoloration. Dissolution of suramin sodium is performed with a bottom-mounted magnetic agitator at a blade tip speed below 3 m/s; higher shear has been observed to increase surface foaming and proteinaceous film formation at the vessel wall. The bulk solution is held for no more than 4 h before filtration. Filtration uses a 0.45 µm polypropylene depth prefilter followed by two 0.22 µm PVDF membrane capsules in series, each providing 0.6 m² membrane area, with integrity tested by forward flow per manufacturer protocol before and after fill. Filled containers are 10 mL Type I borosilicate glass vials with halobutyl rubber stoppers and aluminum flip-off seals. Terminal autoclaving is generally avoided when forced degradation data show heat-related increase in unknown related substances; aseptic processing is selected as the default for heat-sensitive suramin sodium solutions. Light protection is required because photolytic degradation can accelerate the formation of colored naphthalene-sulfonic acid derivatives. In-process controls include pH, osmolality, prefilter differential pressure, and filter integrity. Finished product release testing covers sterility by USP <71>, bacterial endotoxins by USP <85>, subvisible particulates by USP <788>, and visible particulates by the compendial visual inspection method. Because suramin has a narrow therapeutic index and is used in non-food-producing equine and camelid species in many jurisdictions, withdrawal-period labeling does not apply where animals are excluded from human food chains; nevertheless, slaughter restrictions must be stated on labels in markets with dual-use camelids.

Test	Method or Standard	Acceptance Limit
Sterility	USP <71>	No growth after 14 days
Bacterial endotoxins	USP <85>	< 0.5 EU/mg suramin sodium
Subvisible particles	USP <788>	≥ 10 µm: ≤ 6000 per container; ≥ 25 µm: ≤ 600 per container
pH	Potentiometric	6.0–6.5
Osmolality	Freezing point depression	280–320 mOsm/kg
Related substances	HPLC area normalization	Any single unknown ≤ 0.5%; total ≤ 2.0%

What Limits Direct Compression of Suramin Sodium Veterinary Tablets and Capsules?

Direct compression of suramin sodium veterinary tablets is constrained by the high active-to-excipient ratio, needle-like or irregular crystal habit, low bulk density, and surface electrostatic charge developed under low-humidity milling. Powder flow measured by USP <1174> through a 10 mm orifice often falls below 5 g/s, and compressibility by USP <616> can exceed a Hausner ratio of 1.35. Production-scale trials on a rotary tablet press with 8 mm round concave punches show edge chipping and sticking at press speeds above 60 rpm when direct compression is attempted without granulation. Consequently, dry granulation by roller compaction is preferred: suramin sodium is preblended with microcrystalline cellulose PH102 and crospovidone at 2% w/w, then compacted at hydraulic pressure of 30–50 bar with a screen size of 0.8 mm. The granules are lubricated with 0.5% w/w magnesium stearate in a bin blender at 12 rpm for 3 min. Tablets are compressed to hardness of 60–90 N, with disintegration time below 15 min by USP <701>. Content uniformity is verified by USP <905> with acceptance value ≤ 15. For capsule filling, the dry-granulated material is filled on a dosator-type capsule machine into size 1 or 0 hard gelatin capsules, with fill weight controlled to ± 3% of target. Dissolution testing by USP <711> is used as a quality control tool rather than as an in vivo predictor, because suramin sodium has highly pH-dependent aqueous solubility and poor passive permeability across gastrointestinal membranes. The practical production limit is that tableting and capsule filling must be performed in an environment below 40% RH to prevent softening, picking, and film formation on punch faces. If aqueous film coating is applied to tablets, a hydroalcoholic seal coat is required before the aqueous coating step to restrict water uptake at the tablet core surface. For capsule products, desiccant pouches and HDPE bottles with induction-sealed foil liners are used to maintain physical and chemical stability during distribution in humid tropical markets.

Dry oral granule production for individual animal dosing or in-feed administration frequently requires a moisture-protective carrier because suramin sodium batches can exhibit hygroscopic tendency and photolytic discoloration when exposed to unprotected humid storage. A top-spray fluid bed granulation process is used with a Glatt GPCG-30 or equivalent, inlet air temperature at 60°C, product temperature maintained at 30–35°C, and spray rate of 150–250 g/min for a 3% w/w hydroxypropyl methylcellulose binder solution. The powder bed consists of suramin sodium, lactose monohydrate, and pregelatinized starch; after drying, the granulate is screened through a 20–60 mesh sieve system. Loss on drying is controlled below 3.0% by moisture balance at 105°C. Granule flow is measured by USP <1174>, with a target of not less than 12 g/s through a 10 mm orifice for automatic dispensing into sachets or bulk containers. Blend homogeneity after adding flavor-masking agent and glidant is evaluated by sampling 10 locations per blender batch; relative standard deviation should not exceed 5.0%. Because suramin sodium is a polyanionic compound with poor oral permeability, oral powder or granule forms are not interchangeable with injectable treatment for systemic trypanosomiasis; they are restricted to labels or clinical protocols in which gastrointestinal or enteral-site action is specified. Each lot is packaged in aluminum foil laminate pouches with silica gel desiccant, and the seal is tested by vacuum decay per USP <1207>. The granulation area is maintained at 25°C and 40% RH, and material transfer is performed in closed bins to reduce dust exposure because suramin sodium is a sensitizer in some occupational exposure scenarios. Stability screening under 25°C/60% RH and 40°C/75% RH is used to set shelf-life; where published stability data for this specific veterinary granule configuration are limited, the manufacturer must generate forced degradation profiles to support the labeled storage period.

Lyophilized sterile powder for reconstitution is manufactured when terminal heat sterilization is not feasible due to heat-related degradation and moisture sensitivity. The bulk solution is prepared at a suramin sodium concentration equivalent to 100 mg/mL in Water for Injection with 5% w/v mannitol as a cryoprotectant and a sodium phosphate buffer targeting pH 6.5. The solution is sterile-filtered through 0.22 µm PVDF and filled at 2 mL or 5 mL into 10 mL Type I glass vials. Freeze-drying is performed in a lyophilizer with shelf temperature ramped from -45°C to -20°C over 8 h at chamber pressure of 0.15–0.25 mbar for primary drying, followed by secondary drying at 25°C for 6 h. Collapse of the cake during primary drying is a critical process failure; freeze-drying microscopy is used to define the critical collapse temperature, which may lie near -32°C depending on the specific formulation buffer and mannitol ratio. Residual moisture is determined by Karl Fischer titration per USP <921> Method Ia and must remain below 2.0% for batch release. Container closure integrity is evaluated by dye ingress and vacuum decay using USP <1207>. Reconstitution is performed with Water for Injection to the original fill volume; the reconstituted solution should be inspected for cake collapse, discoloration, and subvisible particles before administration. Because the lyophilized cake can become electrostatically charged during unloading, handling in low-humidity packaging suites below 30% RH reduces powder loss from stoppers and vial necks. The lyophilized powder format is used in remote veterinary field clinics where cold-chain storage of aqueous injections is unreliable, but the reconstituted solution remains susceptible to light and should be used promptly after preparation.

Microingredient Premix Homogeneity in Multi-Ton Dry Feed Carriers

Premix manufacture for dry feed carriers requires a two-stage dilution sequence to ensure acceptable homogeneity of suramin sodium at low final inclusion rates. The first stage is microingredient blending in a 500 L ribbon blender equipped with a 12 rpm ribbon shaft and a high-speed intensifier bar. Suramin sodium is first passed through a 0.5 mm cone mill to break agglomerates and reduce oversized particles. A 1:10 dilution is made with ground limestone or rice hulls as carrier, blended for 10 min, then discharged through a 2.5 cm screen to remove soft lumps. The second stage is dilution into a 2000 kg ribbon or paddle mixer with the full feed premix base, targeting a final concentration such that the premix is added to feed at 0.1–1.0 kg/t. Cross-sampling at discharge through a sampling thief at 10 positions shows that homogeneity can be maintained with a coefficient of variation below 5.0% when the microingredient blend is added at the center of the mixer rather than at the end. Segregation after blending is controlled by selecting carrier particle sizes close to the granulated suramin sodium fraction, generally 250–850 µm. Dust generation during transfer is reduced by adding 0.5–1.0% w/w soybean oil or mineral oil to the final premix, but overtreatment with oil beyond 1.0% can cause bridging in bulk bins and reduce flow through auger systems. Because oral suramin sodium does not produce reliable systemic exposure, premix formulations are labeled for only those enteral indications or local protozoal control programs for which regional marketing authorization exists. Packaging in woven polypropylene bags with an inner polyethylene liner and a desiccant pouch is used when storage humidity exceeds 60% RH. Production records should include carrier lot identity, mixing duration, intensifier bar run time, and post-mixing sieve analysis to support batch release under ISO 22000 feed safety management or equivalent regional feed quality standards.

When Suramin Sodium Is Compounded into Oral Solutions for Individual Animal Dosing, Buffering and Light Protection Become Critical Parameters

Oral solutions compounded from suramin sodium API are prepared at low concentration for individual animal dosing in veterinary clinics and research animal facilities. A typical compounded stock solution at 50 mg/mL is prepared in phosphate-buffered saline, adjusted to pH 6.5–7.0, and filtered through a 0.45 µm syringe filter to remove undissolved particulates; the solution is then dispensed into amber polyethylene terephthalate bottles with child-resistant caps. Because suramin sodium is light-sensitive, amber or opaque containers are required, and exposure to direct sunlight during dosing preparation is avoided. The compounded solution is stored at 2–8°C and assigned a beyond-use date not exceeding 24 h unless a longer stability study is available; published data for this specific compounded configuration are limited, so conservative storage is standard. Buffering is critical because acidic pH can cause precipitation of the acidic form of suramin, while strongly alkaline conditions can accelerate hydrolytic degradation of the sulfonic acid side chains. The solution should not be mixed with strong oxidizing agents, cationic drugs, or divalent metal salts in the same administration syringe, because complexation or precipitation may occur. Viscosity at 50 mg/mL is generally low enough for oral gavage through a 6 Fr catheter, but higher concentrations above 100 mg/mL can become difficult to draw through narrow-gauge tubing. Accurate dosing is verified by weight rather than volume for small animals, using a calibrated balance with readability of 0.01 g. The container label lists the exact concentration, preparation date, storage temperature, and the warning that oral absorption is poor and the product is not interchangeable with injectable suramin sodium. In multi-dose clinic settings, aliquoting into single-use oral syringes reduces the risk of microbial growth that can accompany repeated opening of a bulk compounded solution. All preparation steps are documented in accordance with local veterinary compounding regulations and, where applicable, USP <795> for nonsterile compounding or USP <797> when sterile preparation is required.